Skip to content
Clinical Trials – home
SlovakiaBack to Slovakia

Clinical trials in Nove Mesto Nad Vahom – page 12

246 clinical trials in Nove Mesto Nad Vahom, Slovakia. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Nove Mesto Nad Vahom at a glance
246
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

246 trials in Nove Mesto Nad Vahom

Open in trial search

Study on the Effects of Filgotinib for Adults with Active Axial Spondyloarthritis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Hypertriglyceridaemia+1

Not recruiting

Study of Olezarsen (ISIS 678354) for Patients with High Triglycerides and Heart Disease or Severe High Triglycerides

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Hypertriglyceridaemia

Not recruiting

Study of ISIS 678354 for Patients with Severe Hypertriglyceridemia

InvestigationalNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Atrial fibrillation

Not recruiting

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:SlovakiaSlovakia
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International

Arteriosclerosis

Not recruiting

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Psoriatic arthropathy

Not recruiting

Study on the Effectiveness and Safety of Bimekizumab and Risankizumab in Adults with Active Psoriatic Arthritis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Study on Long-Term Safety and Effectiveness of Bimekizumab for Adults with Active Axial Spondyloarthritis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Rheumatoid arthritis

Not recruiting

Study of LY3871801 for Adults with Moderate to Severe Rheumatoid Arthritis

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:LY3871801
  • Sponsor:Eli Lilly & Co.

Study on Long-Term Safety of Secukinumab for Patients with Polymyalgia Rheumatica

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Study on Long-term Safety and Efficacy of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy Using a Drug Combination

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Argenx

Study on Secukinumab and Prednisone for Patients with Polymyalgia Rheumatica Who Have Recently Relapsed

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Novartis Pharma AG

Other cities in Slovakia

The busiest research cities in the country

All 88 cities in Slovakia

Clinical research in Nove Mesto Nad Vahom

What the registry says about research in the country

01 Cardiovascular Diseases

Clinical trial activity in Stara Tura is focused on cardiovascular diseases, with studies involving adults who have atherosclerotic cardiovascular disease and chronic kidney disease. The research is aimed at better understanding how new treatments may lower the risk of serious heart-related events.

  • Testing new approaches for atherosclerotic cardiovascular disease and chronic kidney disease
  • Studying established cardiovascular disease and high cardiovascular risk
  • Evaluating treatment options for hypertension

These trials are designed to assess whether new therapies can improve prevention of major cardiovascular complications and support better long-term outcomes.

02 Cardiometabolic and Kidney-Related Risk

The local research portfolio also addresses overlapping cardiovascular and kidney-related risk, reflecting the close connection between blood vessel disease, blood pressure control, and renal health. This work helps evaluate whether emerging treatments can reduce events such as heart attack, stroke, or heart failure.

  • Improving outcomes in people with high cardiovascular risk
  • Exploring prevention strategies for heart failure and related complications
  • Supporting better control of hypertension in high-risk patients

In this setting, researchers are focusing on whether new therapies can offer stronger protection than standard care for patients most vulnerable to major cardiovascular events.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.